Cardiosense
Manufacturing · Illinois, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
400 N Aberdeen St Ste 900, Chicago, Illi...Phone Number
(312) 725-2211Website
www.cardiosense.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
3
1
1
1
1
About Cardiosense
Cardiosense is developing a digital biomarker platform that utilizes innovative multi-sensor devices and proprietary algorithms to identify early signs of cardiac disease and facilitate personalized treatments. Their offerings include a medical-grade wearable device for patient monitoring and a device-agnostic software for aggregating and analyzing physiological data. The company's advanced clinical AI applies deep learning techniques to raw physiological waveforms for the early detection of diseases. Target clients include healthcare providers seeking cutting-edge technology for enhanced cardiac care and patient monitoring.Explore more
Cardiosense Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cardiosense your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Cardiosense has recently received funding, and reach out quickly before it becomes old news!
Cardiosense, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Cardiosense had a recent Job posting/layoffs
Product Launch: Get notified when Cardiosense launches new products
Earning: See what the market has to say on Cardiosense recently announced quarterly report
Check out if Cardiosense is spiking on competitors!
Funding: Get notified immidiatlly once Cardiosense has new funding data
Congratulate Masked Content for being promoted to Masked Content at Cardiosense
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Cardiosense
Compare insights from companies similar to Cardiosense, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cardiosense is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cardiosense is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cardiosense.
Cardiosense financials insights
Gather financial insights about Cardiosense, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$15.1M
Cardiosense Tech Stack
A closer look at the technologies used by Cardiosense
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Hiring Plans
Cardiosense has more open roles in Engineering & Technical than it has had at any time in the past 6 months. Technologies mentioned include: TensorFlow, PyTorch, and Kubernetes.
Hiring Plans
Open Position
Open Position
Open Position
Cardiosense News & Media
Cardiosense Announces Publication of SEISMIC-HF I Study Results in the Journal of the American College of Cardiology: Heart Failure
CHICAGO--(BUSINESS WIRE)--Cardiosense, a medical AI company transforming the management of cardiovascular disease, today announced the publication of results from its SEISMIC-HF I study in the Journal of the American College of Cardiology: Heart Failure (JACC: Heart Failure). The study demonstrates the ability of Cardiosense's novel machine learning (ML) algorithm to noninvasively estimate pulmonary capillary wedge pressure (PCWP) in patients with heart failure with reduced ejection fraction (HCardiosense Launches Nationwide SEISMIC-HF II Study to Validate Its AI Algorithm for Non-Invasive Heart Failure Management
CHICAGO--(BUSINESS WIRE)--Cardiosense, a medical AI company transforming cardiovascular disease management, today announced the launch of SEISMIC-HF II, a nationwide study to validate the company’s machine learning algorithm for assessing intracardiac filling pressure, an early indicator of acute heart failure decompensation. This milestone marks a critical step forward in advancing Cardiosense’s mission to enable access to smarter, personalized cardiac care for all heart failure patients. TheResults from Cardiosense's SEISMIC-HF I Study of a Machine Learning Model to Non-Invasively Assess Cardiac Filling Pressure Presented as Late-Breaking Science at American Heart Association's 2024 Scientific Sessions
SEISMIC-HF I enrolled a large, demographically diverse population across 15 sites Results are an important step toward enabling widespread, non-invasive hemodynamic-guided heart failure management CHICAGO, Nov. 20, 2024 /PRNewswire/ -- Cardiosense, a medical AI company transforming the...Cardiosense Presents Interim Clinical Study Data for Machine Learning Algorithm to Aid in Heart Failure Management at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 Scientific Symposium
CHICAGO, Oct. 28, 2024 /PRNewswire/ -- Cardiosense, a digital health company developing heart failure management platforms for the early detection of worsening heart failure, today presented clinical data at the Cardiovascular Research Foundation's 2024 annual Transcatheter Cardiovascular...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cardiosense
Sign Up For FreeTo access detailed company insights
Cardiosense is developing a digital biomarker platform that utilizes innovative multi-sensor devices and proprietary algorithms to identify early signs of cardiac disease and facilitate personalized treatments. Their offerings include a medical-grade wearable device for patient monitoring and a device-agnostic software for aggregating and analyzing... Read More
